Showing 1371-1380 of 2088 results for "".
- New Jersey Passes Law Prohibiting Indoor Tanning for Those Under 17https://practicaldermatology.com/news/20130402-new_jersey_passes_law_prohibiting_indoor_tanning_for_those_under_17/2459575/The state of New Jersey recently passed a law that bans minors under the age of 17 years old from using indoor tanning devices. The law passed both the New Jersey House and Senate in February and was signed into law by Gov. Christopher Christie on April 1, 2013. Dirk M. Elston, MD, FAAD, President o
- New York City's Mount Sinai Launches Melanoma and Skin Cancer Centerhttps://practicaldermatology.com/news/new-york-citys-mount-sinai-launches-melanoma-and-skin-cancer-center/2460777/Mount Sinai received a second $10 million gift from the Waldman Family to open the Kimberly and Eric J. Waldman Melanoma and Skin Cancer Center at Mount Sinai. Housed within the Kimberly and Eric J. Waldman Department of Dermatology at the May
- Biologic Costs for Plaque Psoriasis Doubled Since 2007, Study Findshttps://practicaldermatology.com/news/biologic-costs-for-plaque-psoriasis-double-since-2007-study-finds/2474189/A new analysis shows the average net annual cost of first-line biologic treatments for plaque psoriasis more than doubled between 2007 and 2021, rising from $21,236 to $47,125. The study researchers, publishing online in J
- Humira Biosimilar Simlandi Now Available in the UShttps://practicaldermatology.com/news/humira-biosimilar-simlandi-now-available-us/2463126/Teva Pharmaceuticals and Alvotech announced the availability of Simlandi (adalimumab-ryvk) injection in the US as an interchangeable biosimilar to Humira. Simlandi is indicated for the treatment of adult plaque psoriasis and adult hidradenitis suppurativa, as well as adult rheumatoid arthritis, j
- Research IDs New Psoriasis Inflammation Pathwayhttps://practicaldermatology.com/news/research-ids-new-psoriasis-inflammation-pathway/2463125/Researchers from a recent study have identified a key biological pathway responsible for the inflammation seen in psoriasis, with potential implications for other inflammatory diseases like atopic dermatitis, allergic dermatitis, and hidradenitis suppurativa. The study, published in the j
- Partial Irreversible Electroporation May Help Extinguish Burn Scars Before They Starthttps://practicaldermatology.com/news/partial-irreversible-electroporation-may-help-extinguish-burn-scars-before-they-start/2458470/A new non-invasive method may help prevent burn scarring caused by the proliferation of collagen cells, report researchers from Tel Aviv University and Harvard University in the J
- Joseph C. Papa Assumes Role Of Chairman And Chief Executive Officer Of Valeanthttps://practicaldermatology.com/news/joseph-c-papa-assumes-role-of-chairman-and-chief-executive-officer-of-valeant/2458580/Joseph C. Papa has assumed the role of Chairman and Chief Executive Officer at Valeant Pharmaceuticals International, Inc. As previously announced, Joseph C. Papa succeeds J. Michael Pearson. &quo
- Ouchless Needle Announces First Exclusive International Distribution Agreement with Device Technologieshttps://practicaldermatology.com/news/20120501-ouchless_needle_announces_first_exclusive_international_distribution_agreement_with_device_technologies/2459811/Ouchless Needle by the BellaNovus Development Company announced their first international exclusive distribution agreement with Device Technologies for Australia and New Zealand. Developed by aesthetic plastic surgery innovator Marc J. Sa
- KYTHERA Biopharmaceuticals to Present at 32nd Annual J.P. Morgan Healthcare Conferencehttps://practicaldermatology.com/news/20140107-kythera_biopharmaceuticals_to_present_at_32nd_annual_jp_morgan_healthcare_conference/2459378/KYTHERA Biopharmaceuticals, Inc. (Nasdaq:KYTH) today announced that Keith Leonard, president and chief executive officer, will present at the 32nd Annual J.P. Morgan Healthcare Conference in San Francisco, CA.
- Evaxion’s AI-Powered Cancer Vaccine Demonstrates High Response in Early Studyhttps://practicaldermatology.com/news/evaxions-ai-powered-cancer-vaccine-demonstrates-high-efficacy-in-early-study/2467073/Evaxion Biotech A/S, a firm specializing in AI-driven immunology vaccines, recently published data from its Phase 1 dose escalation study of the EVX-01 personalized cancer vaccine for metastatic melanoma showing almost 70% clinical response from patients. The study, published in the J